{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:10:16Z","timestamp":1740136216723,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T00:00:00Z","timestamp":1499731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T00:00:00Z","timestamp":1499731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR000422"],"award-info":[{"award-number":["TL1TR000422"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12936-017-1921-x","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T23:20:22Z","timestamp":1499728822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Donor support for quality assurance and pharmacovigilance of anti-malarials in malaria-endemic countries"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2171-821X","authenticated-orcid":false,"given":"Stephanie D.","family":"Kovacs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianna M.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Stergachis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,11]]},"reference":[{"key":"1921_CR1","unstructured":"WHO World Malaria Report 2015. Geneva: World Health Organization; 2015."},{"key":"1921_CR2","unstructured":"Geneva, World Health Organization. Overview of malaria treatment. Geneva: World Health Organization; 2016. \n                    http:\/\/www.who.int\/malaria\/areas\/treatment\/overview\/en\/\n                    \n                  . Accessed 30 Oct 2016."},{"key":"1921_CR3","unstructured":"Kaiser family foundation. The US government and global malaria efforts. 2016. \n                    http:\/\/kff.org\/global-health-policy\/fact-sheet\/the-u-s-government-and-global-malaria\/\n                    \n                  . Accessed 17 Jul 2016."},{"key":"1921_CR4","unstructured":"The Global Fund to fight AIDS tuberculosis and malaria financials. 2016. \n                    http:\/\/www.theglobalfund.org\/en\/financials\/\n                    \n                  ."},{"key":"1921_CR5","unstructured":"WHO. Assessment of the safety of artemisinin compounds in pregnancy: report of two joint informal consultations convened in 2006. Geneva: World Health Organization; 2006."},{"key":"1921_CR6","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1371\/journal.pmed.0050187","volume":"5","author":"S Dellicour","year":"2008","unstructured":"Dellicour S, ter Kuile FO, Stergachis A. Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Med. 2008;5:e187.","journal-title":"PLoS Med."},{"key":"1921_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.reprotox.2009.05.002","volume":"28","author":"RL Clark","year":"2009","unstructured":"Clark RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol. 2009;28:285\u201396.","journal-title":"Reprod Toxicol"},{"key":"1921_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/bdrb.20163","volume":"83","author":"RL Clark","year":"2008","unstructured":"Clark RL, Arima A, Makori N, Nakata Y, Bernard F, Gristwood W, et al. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res B Dev Reprod Toxicol. 2008;83:418\u201334.","journal-title":"Birth Defects Res B Dev Reprod Toxicol."},{"key":"1921_CR9","unstructured":"European medicines agency. Eurartesim. 2013. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001199\/human_med_001450.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true\n                    \n                  . Accessed 26 May 2015."},{"key":"1921_CR10","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1128\/AAC.02667-14","volume":"58","author":"J Manning","year":"2014","unstructured":"Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, et al. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin\u2013piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother. 2014;58:6056\u201367.","journal-title":"Antimicrob Agents Chemother"},{"key":"1921_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pt.2010.08.005","volume":"27","author":"JK Baird","year":"2011","unstructured":"Baird JK, Surjadjaja C. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 2011;27:11\u20136.","journal-title":"Trends Parasitol."},{"key":"1921_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40264-016-0429-6","volume":"39","author":"M Russom","year":"2016","unstructured":"Russom M, Tesfai D, Gebregiorgis S, Usman A, Mihreteab S, Bahta I, et al. Artesunate\/amodiaquine-induced acute extrapyramidal reactions in children and younger adults: case series assessment. Drug Saf. 2016;39:763\u20138.","journal-title":"Drug Saf"},{"key":"1921_CR13","doi-asserted-by":"publisher","first-page":"ofv170","DOI":"10.1093\/ofid\/ofv170","volume":"3","author":"RJ Burger","year":"2016","unstructured":"Burger RJ, van Eijk AM, Bussink M, Hill J, ter Kuile FO. Artemisinin-based combination therapy versus quinine or other combinations for treatment of uncomplicated Plasmodium falciparum malaria in the second and third trimester of pregnancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3:ofv170.","journal-title":"Open Forum Infect Dis."},{"key":"1921_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1475-2875-10-144","volume":"10","author":"J Achan","year":"2011","unstructured":"Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10:144.","journal-title":"Malar J."},{"key":"1921_CR15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1473-3099(12)70064-6","volume":"12","author":"GML Nayyar","year":"2012","unstructured":"Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis. 2012;12:488\u201396.","journal-title":"Lancet Infect Dis."},{"key":"1921_CR16","unstructured":"WHO. Pharmacovigilance\u202f: ensuring the safe use of medicines. Geneva, World Health Organization, 2004."},{"key":"1921_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1371\/journal.pmed.1001054","volume":"8","author":"N Bakare","year":"2011","unstructured":"Bakare N, Edwards IR, Stergachis A, Pal S, Holmes CB, Duncombe C, et al. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS Med. 2011;8:6\u20139.","journal-title":"PLoS Med."},{"key":"1921_CR18","unstructured":"WHO. Minimum requirements for a functional pharmacovigilance system. Geneva: World Health Organization; 2010."},{"key":"1921_CR19","unstructured":"Strengthening pharmaceutical systems. Safety of medicines in sub-Saharan Africa: assessment of pharmacovigilance systems and their performance. 2011."},{"key":"1921_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","volume":"39","author":"H Ampadu","year":"2016","unstructured":"Ampadu H, Hoekman J, de Bruin M, Pal S, Olsson S, Sartori D, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports. Drug Saf. 2016;39:335\u201345.","journal-title":"Drug Saf"},{"key":"1921_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1475-2875-10-57","volume":"10","author":"A Kuemmerle","year":"2011","unstructured":"Kuemmerle A, Dodoo ANO, Olsson S, Van Erps J, Burri C, Lalvani PS. Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring. Malar J. 2011;10:57.","journal-title":"Malar J."},{"key":"1921_CR22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11536390-000000000-00000","volume":"33","author":"S Olsson","year":"2010","unstructured":"Olsson S, Pal S, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries. Drug Saf. 2010;33:689\u2013703.","journal-title":"Drug Saf"},{"key":"1921_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1475-2875-9-148","volume":"9","author":"A Stergachis","year":"2010","unstructured":"Stergachis A, Bartlein RJK, Dodoo A, Nwokike J, Kachur SP. A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President\u2019s Malaria Initiative proposals. Malar J. 2010;9:148.","journal-title":"Malar J."},{"key":"1921_CR24","volume-title":"Disease control priorities in developing countries","author":"P Nsubuga","year":"2006","unstructured":"Nsubuga P, White M, Thacker S, Anderson M, Blount S, Broome C, et al. Public health surveillance: a tool for targeting and monitoring interventions. In: Jamison D, Breman J, Measham A, editors. Disease control priorities in developing countries. 2nd ed. Washington DC: Oxford University Press; 2006.","edition":"2"},{"key":"1921_CR25","unstructured":"WHO. Health systems strengthening glossary. Geneva: World Health Organization; 2016. \n                    http:\/\/www.who.int\/healthsystems\/hss_glossary\/en\/index5.html\n                    \n                  . Accessed 14 Jun 2016."},{"key":"1921_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1471-2393-12-89","volume":"12","author":"U Mehta","year":"2012","unstructured":"Mehta U, Clerk C, Allen E, Yore M, Sevene E, Singlovic J, et al. Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings. BMC Pregnancy Childbirth. 2012;12:89.","journal-title":"BMC Pregnancy Childbirth."},{"key":"1921_CR27","unstructured":"The Global Fund to fight AIDS tuberculosis and malaria. The global fund strategy 2012\u20132016: investing for impact. 2016. \n                    http:\/\/www.theglobalfund.org\/en\/strategy\/\n                    \n                  . Accessed 17 Jun 2016."},{"key":"1921_CR28","unstructured":"World Health Organization, UNAIDS. Technical guidance note for Global Fund HIV proposals pharmacovigilance for antiretroviral drugs. 2011. \n                    http:\/\/www.who.int\/hiv\/pub\/tech_guidance_pharma.pdf\n                    \n                  . Accessed 14 Oct 2016."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-017-1921-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-017-1921-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-017-1921-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T07:17:04Z","timestamp":1589527024000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-017-1921-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1186\/s12936-017-1921-x","relation":{},"ISSN":["1475-2875"],"issn-type":[{"type":"electronic","value":"1475-2875"}],"subject":[],"published":{"date-parts":[[2017,7,11]]},"assertion":[{"value":"7 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"282"}}